Why the study?
Pericardial synovial sarcomas are very rare tumors with dismal prognosis and limited data, prompting a description of clinical features and prognostic factors.
What are the clinical features and prognostic factors for survival in patients with primary pericardial synovial sarcoma?
What are the clinical features and prognostic factors for survival in patients with primary pericardial synovial sarcoma?
Answers are grounded in this paper and cite their sources.
Complete surgical resection is an independent prognostic factor for survival in pericardial synovial sarcoma, and targeted therapy with pazopanib may offer a safe and effective treatment option.
BACKGROUND: Pericardial synovial sarcomas (PSS) are very rare tumors, with dismal prognosis and limited data. We describe the clinical features and identify prognostic factors of primary PSS. CASE REPORT: We describe the case of a 56-year-old male patient with PSS managed by the multidisciplinary team of thoracic oncology. The therapeutic plan comprised surgery, chemotherapy, stereotactic radiosurgery and targeted therapy, with excellent results. MATERIALS AND METHODS: Data from 37 cases reported in English during the past 20 years were gathered and analyzed. PSS was found to occur at a mean age of 36±17.082 (range=13-67) years. Survival analysis was performed on 20 cases with follow-up of at least 6 months. CONCLUSION: Only complete resection of the tumor seems to be an independent prognostic factor. To our knowledge, this is the first report on the safety and effectivity of pazopanib in PSS and may provide guidance for similar cases in the future.
No takes yet. Share an insight, caveat, or question.
Durán et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: